Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fentanyl + midazolam (Hôpital Maisonneuve-Rosemont)
- Development stage
- Unknown
- Lead developer
- Hôpital Maisonneuve-Rosemont
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fentanyl and midazolam is a combination of a synthetic opioid analgesic and a benzodiazepine sedative. In the clinical study conducted by Maisonneuve-Rosemont Hospital, this combination was evaluated as a low-dose intravenous premedication to facilitate the induction of general anesthesia using sevoflurane. Fentanyl acts as a potent agonist at the mu-opioid receptor, providing analgesia and suppressing airway reflexes, while midazolam functions as a positive allosteric modulator of the GABA-A receptor, inducing sedation and reducing preoperative anxiety. The combination is intended to shorten the time to loss of consciousness and improve the clinical conditions for the insertion of airway devices like the ProSeal laryngeal mask airway during minor elective surgeries.
- Other names
- Fentanyl and MidazolamLow Dose Fentanyl/MidazolamFentanyl/Midazolam Premedication
02
Targets
MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on fentanyl + midazolam (Hôpital Maisonneuve-Rosemont).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fentanyl + midazolam (Hôpital Maisonneuve-Rosemont).